Company: BNBX
Filing Date: 2025-01-17
Form Type: 424B3
Source: 0001104659-25-004510
Chunk: 7

Company: BNB PLUS CORP.
Filing Date: 2025-01-17
Form: 424B3
Chunk 7
---
                                                    
 via PCR is pure, resulting in only large quantities of only the target DNA sequence. Unwanted DNA sequences such as the plasmid backbone 
 and antibiotic resistance genes, inherent to plasmid DNA, are not present in LineaDNA.                                                   |
| · | Simplicity – The                                                                                                                         
 production of LineaDNA is streamlined relative to plasmid-based DNA production. LineaDNA requires only four primary ingredients,         
 does not require living cells or complex fermentation systems and does not require multiple rounds of purification.                      |
| · | Flexibility –                                                                                                                            
 DNA produced via the LineaDNA platform can be easily chemically modified to suit specific customer applications. In addition, the        
 LineaDNA platform can produce a wide range of complex DNA sequences that are difficult to produce via plasmid-based DNA production       
 platforms. These complex sequences include inverted terminal repeats and long homopolymers such as polyadenylation sequences (poly       
 (A) tail) important for gene therapy and mRNA therapies, respectively.                                                                   |

Preclinical studies conducted by the Company
have shown that LineaDNA is substitutable for plasmid DNA in numerous nucleic acid-based therapies, including:

| · | DNA vaccines; |

| · | DNA templates to produce          
 RNA, including mRNA therapeutics; |

| · | adoptive cell therapy (CAR-T) 
 manufacturing; and            |

| · | homology-directed repair     
 (HDR)-mediated gene editing. |

Further, we believe that LineaDNA is also
substitutable for plasmid DNA in the following nucleic acid-based therapies:

| · | viral vector manufacturing            
 for in vivo and ex vivo gene editing; |

| · | clustered regularly interspaced                      
 short palindromic repeats-mediated gene therapy; and |

| · | non-viral gene therapy. |

Linea IVT Platform

The number of mRNA therapies under development
is growing at a rapid rate, thanks in part to the success of the mRNA COVID-19 vaccines. mRNA therapeutics are produced via a process
called in vitro transcription (“IVT”) that requires DNA as a starting material. As of the third quarter of calendar
2024, there were over 450 mRNA therapies under development, with the majority of these therapies (67%) in the preclinical stage (Source:
ASGCT Gene, Cell & RNA Therapy Landscape: Q3 2024 Quarterly Report). The Company believes that the mRNA market is in a nascent
stage that represents a large growth opportunity